0000000001227895

AUTHOR

A. Zanetto

showing 3 related works from this author

Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S01688278173…

2018

It has come to our attention that the PITER framework investigator, Alessandro Federico, was incorrectly listed as F. Alessandro in the original manuscript. Please note that the correct name of this author is Alessandro Federico (2nd University of Naples). The correct list of PITER investigators is in the footnote below.

HepatologyHepatitis B; EASL guidelines; Treatment; Interferon; Entecavir; Tenofovir; TAF; HBsAg; Hepatocellular carcinoma; HBV DNA; HBV reactivation; Mother to child transmissionHepatocellular carcinomaHBV reactivationEASL guidelinesHepatitis BEntecavirTreatmentHBsAgTAFHBV DNAMother to child transmissionInterferonTenofovirEASL guideline
researchProduct

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

2017

Background & Aims Premenopausal women who are HCV positive (HCV+) have failing ovarian function, which is likely to impact their fertility. Thus, we investigated the reproductive history, risk of infertility, and pregnancy outcomes in women of childbearing age who were HCV+. Methods Three different groups were studied: (1) Clinical cohort: 100 women who were HCV+ and also had chronic liver disease (CLD), age matched with 50 women who were HBV+ with CLD and with 100 healthy women; all women were consecutively observed in three gastroenterology units in hospitals in Italy; (2) 1,998 women who were HCV+ and enrolled in the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)…

Anti-Mullerian hormone; Antiviral therapy; HBV; HCV; Sustained viral response; HepatologyInfertilitymedicine.medical_specialtySustained viral responsemedia_common.quotation_subjectFertilityAnti-Müllerian hormoneAntiviral therapyMiscarriage03 medical and health sciences0302 clinical medicineHBVMedicineProspective cohort studymedia_commonGynecologyAnti-Müllerian hormone Antiviral therapy HBV HCV Sustained viral response030219 obstetrics & reproductive medicineHepatologybusiness.industryObstetricsAnti-Müllerian hormone; Antiviral therapy; HBV; HCV; Sustained viral responseAnti-Mullerian hormonemedicine.diseaseAnti-Müllerian hormoneGestational diabetesCohortHCV030211 gastroenterology & hepatologyAnti-Müllerian hormone; Antiviral therapy; HBV; HCV; Sustained viral response; HepatologybusinessLive birthCell aging
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct